Will Branchett still remembers the early mornings when chilled courier boxes arrived at the Crick Institute, racing down the M1 with bronchoalveolar lavage fluid from Leicester—liquid windows into the lungs of people recently exposed to tuberculosis. Inside those samples, hidden in the genetic activity of immune cells, lay clues to a mystery that has long baffled scientists: why do only 5% to 10% of people infected with Mycobacterium tuberculosis go on to develop active disease? Now, thanks to a meticulous study led by Branchett and Anne O’Garra at the Francis Crick Institute in London, the answer appears to hinge on a delicate immune balancing act in the very first days after infection.
For years, researchers assumed active TB stemmed from a weak immune response. But O’Garra’s landmark 2010 study turned that idea on its head, revealing that active TB was instead linked to a strong—but misdirected—inflammatory signal driven by type I interferon, a molecule better known for fighting viruses. That discovery shifted the field. Still, blood tests could only go so far. The real battle begins in the lungs, and to see it up close, the team needed to analyze immune activity at the site of infection.
By studying airway fluid from household contacts of TB patients, the researchers uncovered two starkly different immune trajectories. In those who later developed active TB, the lungs were flooded with neutrophils—first-responder immune cells—many of which had activated type I interferon-related genes. These neutrophils also churned out CXCL8, a chemical beacon that draws even more neutrophils, potentially fueling a self-sustaining storm of inflammation. Meanwhile, the T cells meant to control the infection showed signs of exhaustion and death, overwhelmed before they could act.
In contrast, people who controlled the infection had fewer neutrophils and T cells that remained calm, resilient, and “stem-like”—capable of long-term vigilance. This balance, the team found, wasn’t unique to humans. The same patterns emerged in nonhuman primate and mouse studies, reinforcing the idea that early immune dynamics in the lung are a critical tipping point.
The implications are profound. If confirmed in larger studies, these findings could lead to early biomarkers that predict who will develop TB—offering a chance to intervene before symptoms arise. With 25% of the world’s population latently infected, such a tool could transform how we prevent one of the oldest and deadliest diseases on Earth. As Branchett puts it, 'It’s about getting the balance right.' The future of TB prevention may not lie in stronger attacks on the bacteria, but in smarter stewardship of the body’s own defenses.